PDCD1 and Miyoshi myopathy: In a previous study including 125 MM patients treated with an anti-PD1 agent, we highlighted the predictive role of PD1.5 C > T, PD1.7 T > C and PD-L1 + 8293 C > A SNVs on the occurrence of immune-related adverse events (irAEs), with PD1.7 SNV also showing a prognostic value [4].